<?xml version="1.0" encoding="UTF-8"?><CAS version="2"><uima.cas.Sofa _indexed="0" _id="1" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="P10380232A0000 OBJECTIVE: To perform a cost-effectiveness analysis (CEA) between a standard antiemetic regimen-chlorpromazine + dexamethasone (CPM-DEX)- and a 5-HT3 receptor antagonist-tropisetron (TROP)--in the control of acute emesis induced by highly emetogenic chemotherapy in children, considering two analytic perspectives: hospital and patients."/><uima.tcas.DocumentAnnotation _indexed="1" _id="8" _ref_sofa="1" begin="0" end="352" language="x-unspecified"/><edu.cmu.tanl.type.gene _indexed="1" _id="13" _ref_sofa="1" begin="47" end="49" Gene="CEA"/><edu.cmu.tanl.type.gene _indexed="1" _id="18" _ref_sofa="1" begin="127" end="139" Gene="5-HT3 receptor"/></CAS>